Purpose: Endothelial nitric oxide synthase (eNOS) plays a central role in regulating vascular tone, blood flow, and microvascular permeability. Endothelial dysfunction, including eNOS dysfunction, is an early biomarker of vascular disease. This study aimed to show that myocardial T 1 mapping during nitric oxide synthase (NOS) inhibition could assess coronary microvascular eNOS function. Methods: Wild-type mice, eNOS À/À mice, and wild-type mice fed a high-fat diet underwent T 1 mapping at baseline and for 20 min after injection of N G -nitro-L-arginine methyl ester (LNAME), a NOS inhibitor. First-pass perfusion MRI was performed in wildtype mice at baseline and 5 min after LNAME injection. Results: T 1 mapping detected an increase in myocardial T 1 5 min after an injection of 4 mg/kg LNAME compared with baseline in control mice (T 1 ¼ 1515 6 30 ms with LNAME versus T 1 ¼ 1402 6 30 ms at baseline, P < 0.05). No change in myocardial T 1 after LNAME injection was observed in eNOS À/À mice. The change in T 1 after LNAME injection was less in high-fat-diet mice (DT 1 ¼ 31 6 14 ms at 12 weeks of diet and DT 1 ¼ 16 6 17 ms at 18 weeks of diet) compared with mice fed a standard diet (DT 1 ¼ 113 6 15 ms), with P < 0.05. First-pass MRI measured similar perfusion at baseline and 5 min after LNAME injection. Conclusions: NOS inhibition causes an increase in myocardial T 1 in healthy mice, and this effect is mediated through eNOS. T 1 mapping during NOS inhibition detects coronary microvascular eNOS dysfunction in high-fat-diet mice. T 1 mapping during NOS inhibition may be useful in preclinical studies aiming to investigate mechanisms underlying and therapies for coronary microvascular eNOS dysfunction. Magn Reson
INTRODUCTION
The vascular endothelium is a monolayer of cells that lines the inner surface of blood vessels. Endothelial nitric oxide synthase (eNOS), an enzyme that produces nitric oxide (NO) in the vascular endothelium, plays a central role in regulating vascular properties such as tone, regional blood flow, and microvascular permeability. Cardiovascular risk factors such as obesity (1) , diabetes mellitus (2) , and hypertension (3) lead to excess production of superoxide or, more generally, reactive oxygen species, in the vascular wall. The resulting vascular oxidative stress leads to a process referred to as eNOS uncoupling, in which eNOS dysfunction occurs and eNOS is converted from an NO producer to a superoxide producer (4) . Under these conditions, the central roles of eNOS in endothelial function are compromised, and instead of promoting vascular health, eNOS contributes to oxidative stress and endothelial dysfunction. A minimally invasive imaging method to assess eNOS function would enable the study of mechanisms leading to eNOS dysfunction and of potential therapies targeting eNOS, as eNOS dysfunction presently is not fully understood and there are limited therapies that promote normal eNOS function.
Previous studies have shown that pharmacological inhibition of nitric oxide synthase (NOS) with agents such as N G -nitro-L-arginine methyl ester (LNAME) rapidly depletes the local vessel wall NO concentration, leading to a rapid increase in microvascular permeability, protein efflux from the blood to the extracellular space, and microvascular fluid efflux (5) (6) (7) (8) (9) (10) . We hypothesized that MRI T 1 mapping of the heart during NOS inhibition could detect changes in compartmental water content resulting from acute changes in microvascular permeability and fluid efflux. Furthermore, we hypothesized that these changes are mediated through eNOS and would be diminished in a disease state with eNOS dysfunction. The overall goal of this study was to show that T 1 mapping during pharmacological NOS inhibition could be used to assess vascular eNOS function in the heart.
METHODS

Experimental Design
We first sought to show that T 1 mapping of the heart during NOS inhibition could detect an increase in myocardial T 1 . For these studies, healthy 19-week-old male wild-type (WT) C57Bl/6 mice underwent T 1 mapping before and after injection of a NOS inhibitor. The pharmacological agent LNAME was chosen as the NOS inhibitor, as it is tolerated by both animals (5, 9, 11, 12) and humans (13) when injected intravenously, and is commercially available (Product number N5751, Sigma-Aldrich, St. Louis, MO, USA). The LNAME was dissolved in sterile saline, and two doses of LNAME (2 mg/kg (n ¼ 8) and 4 mg/kg (n ¼ 6)) were tested. The bolus concentrations were 1 and 2 mg/mL, respectively, and the total injection volume ranged from 55 to 60 mL. The data acquisition protocol for the LNAME T 1 mapping experiments is shown in Figure 1a .
Next, we tested the hypothesis that the change in myocardial T 1 during NOS inhibition is mediated specifically through eNOS. For these studies, we performed experiments in 13-week-old male eNOS knockout (eNOS À/À ) mice on a C57Bl/6 background (n ¼ 7) (stock number 002684 j eNOS KO, Jackson Laboratory, Bar Harbor, ME, USA) using the LNAME T 1 mapping protocol shown in Figure 1a and with an LNAME dose of 4 mg/kg.
Previous studies have shown that pharmacological agents such as adenosine that cause vasodilation and changes in vascular tone and perfusion can also cause a detectable increase in myocardial T 1 (14) . To exclude the possibility that increases in myocardial T 1 during NOS inhibition may be caused by potential vasodilatory effects, we measured myocardial perfusion at baseline and during NOS inhibition using gadolinium-enhanced first-pass perfusion MRI (15) in male WT control mice (n ¼ 6). As shown in the data acquisition protocol for the LNAME first-pass perfusion experiments (Fig. 1b) , baseline and post-LNAME first-pass perfusion images were acquired within the same imaging session, and each used a 0.1-mmol/kg dose of gadolinium-diethylenetriaminepentacetate (Gd-DTPA). The bolus concentration of Gd solution was 0.05 M. The total injection volume, which included two injections of Gd solution and one injection of LNAME solution, ranged from 160 to 180 mL. A 15-min waiting period between first-pass measurements was used to allow contrast agent washout. Post-LNAME perfusion was measured 5 min after intravenous injection of LNAME to match the timing of the LNAME T 1 mapping experiment.
Finally, we sought to show that LNAME T 1 mapping could detect eNOS dysfunction in a mouse model of cardiac microvascular disease. For the disease model, we chose male C57BL/6 mice fed a high-fat diet (HFD), as this model exhibits hallmarks of diabetic cardiomyopathy (16, 17) , and has previously been shown to develop coronary endothelial dysfunction (18) (19) (20) . To test the hypothesis that T 1 mapping with NOS inhibition can detect coronary microvascular eNOS dysfunction in HFD mice, mice underwent HFD feeding (60% calories from fat, Diet 12492, Research Diets Inc, New Brunswick, NJ, USA) for 12 (18 weeks old, n ¼ 10) and 18 weeks (24 weeks old, n ¼ 10); at each time point, MRI T 1 mapping with 4-mg/kg LNAME was performed. The LNAME solution injection volume ranged from 65 to 110 mL.
Animal Handling
All animal studies were performed under protocols that comply with the Guide for the Care and Use of Laboratory Animals (NIH publication no. 85-23, revised 1996) and were approved by the Animal Care and Use Committee at our institution. An indwelling tail vein catheter was established to deliver LNAME (Sigma-Aldrich) and/or Gd-DTPA (Magnevist, 0.1 mmol/kg body weight) during MRI. Body temperature was maintained at 36 6 0.5 C using circulating warm water, and anesthesia was maintained using 1.25% isoflurane in O 2 during MRI.
Magnetic Resonance Imaging Acquisitions
Magnetic resonance imaging was performed on a 7T Clinscan system (Bruker, Ettlingen, Germany) using 30-or 35-mm-diameter birdcage radiofrequency coils and an MR-compatible physiological monitoring and gating system for mice (SA Instruments Inc, Stony Brook, NY, USA). The larger-diameter radiofrequency coil was used when necessary to accommodate the heavier HFD mice. Localizer imaging was performed to select a midventricular short-axis slice.
T 1 mapping MRI was performed using a spiral LookLocker T 1 -mapping method for mice combined with cardiorespiratory gating, as previously described (21) . The technique uses fuzzy clustering of spiral k-space interleafs (22) . Using k y -t undersampling with randomness and a low-rank compressed-sensing reconstruction (23), the acquisition was rate-2 accelerated, providing a scan time of 7 min.
First-pass Gd-enhanced MRI was performed using a dual-contrast saturation-recovery sequence with k y -t undersampling and a motion-compensated compressedsensing reconstruction algorithm as recently described (15) . Briefly, a saturation pulse is applied after detection of the electrocardiogram R-wave; thereafter, two slices are acquired in each cardiac cycle: the arterial input function (AIF) and the tissue function (TF , slice thickness ¼ 1 mm, number of frames ¼ 300, acceleration rate ¼ 2, AIF saturation delay ¼ 24 ms with centrically ordered phase encoding, and TF saturation delay ¼ 84 ms with linearly ordered phase encoding. Twenty phase-encode lines were acquired for each AIF image, and 20 lines were acquired for each TF image. Contrast agent was injected intravenously 10 s after the start of the first-pass acquisition. Proton density-weighted images were acquired at the end of the acquisition to normalize signal intensities for perfusion analysis. All imaging parameters were kept the same for proton density-weighted image acquisitions compared with the saturation recovery portion of the image acquisition, except that no saturation pulse was applied after detection of the electrocardiogram R-wave, and a flip angle of 5 was used.
Image Analysis
Image reconstruction and analysis were performed in MATLAB (MathWorks, Natick, MA, USA). Undersampled T 1 mapping and first-pass perfusion images were reconstructed using block low-rank sparsity with motion guidance (BLOSM) (23) . For the respiratory-gated T 1 mapping images which did not suffer from respiratory motion, motion guidance was not used; instead, a single block covering the entire image was used, such that the block low-rank sparsity with motion guidance reconstruction reduced to a simple low-rank reconstruction method. To quantify myocardial T 1 , regions of interest for the myocardium were drawn manually and included the entire leftventricular myocardial area within a slice, using conservative delineation of the endocardial and epicardial borders. Signal intensity-time curves were fitted to the following equation:
Þ. An optimal fit of the model parameters M 0 , M z (0), and T 1 was obtained by minimizing the mean squared error. To quantify myocardial blood flow, perfusion analysis was performed as previously described (15) . Briefly, regions of interest for blood and myocardium were drawn, and signal intensity was normalized by proton density-weighted images. Normalized signal intensity was converted to T 1 , and T 1 was converted to Gd concentration using methods described by Cernicanu and Axel (24), and myocardial blood flow was quantified using Fermi deconvolution (25) .
Statistical Analysis
Statistical analyses were performed using SigmaPlot (Systat Software Inc, Point Richmond, CA, USA). Changes in myocardial T 1 and absolute myocardial blood flow were analyzed for various experimental groups of mice at various time points using analysis of variance (ANOVA)
Intravenous administration of 2 and 4 mg/kg LNAME caused a significant decrease in heart rate in control mice (*P < 0.01). The 4-mg/kg LNAME injection also caused a significant decrease in heart rate in HFD mice but not in eNOS À/À mice.
FIG. 3. a:
Example anatomical image used to visualize myocardial borders. R 1 maps of the heart acquired before (b) and 5 min after (c) injection of 4 mg/kg LNAME, demonstrating the decrease in R 1 observed in response to NOS inhibition. d: Example myocardial T 1 relaxation curves before and 5 min after 4 mg/kg LNAME. e: Time course of myocardial T 1 after intravenous injection of LNAME at two doses. Myocardial T 1 measured 5 min after 4-mg/kg LNAME injection was higher than at baseline (*P < 0.05) and was higher than 5 min after 2-mg/kg LNAME ( # P < 0.05).
and the t-test, as appropriate. All values in the text, tables, and graphs are presented as mean 6 standard error.
RESULTS
Nitric Oxide Synthase Inhibition Causes an Increase in Myocardial T 1
Intravenous administration of 2-and 4-mg/kg LNAME caused a significant decrease in heart rate in control mice (Fig. 2) . The results of our studies performing T 1 mapping after infusion of LNAME in WT mice are shown in Figure 3 . The average area of the myocardial regions of interest among all mice was 134 6 4 pixels or 7.1 6 0.2 mm 2 . An example showing the T 1 lengthening effect of NOS inhibition is shown in Figures 3b and 3c, where the R 1 (R 1 ¼ 1/T 1 ) map 5 min after injection of 4-mg/kg LNAME (Fig. 3c) shows a reduction in myocardial R 1 compared with baseline (Fig. 3b) . The same data displayed as myocardial T 1 relaxation curves before and 5 min after LNAME injection illustrate the quality of the Look-Locker measurement data, and show the T 1 lengthening effect of LNAME (Fig. 3d) . Figure 3e summarizes the data from all mice, and shows that T 1 mapping after the injection of LNAME detected a transient increase in T 1 , as T 1 was elevated at 5 min after injection (T 1 ¼ 1515 6 30 ms with 4-mg/kg LNAME versus T 1 ¼ 1402 6 30 ms at baseline, P < 0.05). T 1 decreased toward its baseline value at 20 min after injection. Two-way ANOVA also showed that myocardial T 1 measured 5 min after a 4-mg/kg LNAME injection was significantly FIG. 5. Myocardial perfusion is similar before and after LNAME injection. a: Example AIF and TF curves from before and after LNAME acquisitions. b: Myocardial perfusion was 6.2 6 0.4 mL/g/min at baseline and 6.1 6 0.6 mL/g/min after LNAME. greater than the T 1 measured 5 min after a 2-mg/kg LNAME injection (P < 0.05).
LNAME-Induced Myocardial T 1 Increase Is Mediated Through eNOS
In our second set of experiments, we performed LNAME T 1 mapping in eNOS À/À mice. Intravenous administration of 4-mg/kg LNAME caused no change in heart rate in eNOS À/À mice (Fig. 2) . As shown in Figure 4 , no difference was observed in R 1 maps of a sample eNOS À/À mouse between baseline (Fig. 4b) and after LNAME injection (Fig. 4c) . The graph shown in Figure 4d summarizes the results of T 1 mapping after injection of 4-mg/kg LNAME in WT and eNOS À/À mice, showing that although LNAME caused a significant and transient increase in myocardial T 1 in WT mice, the effect was completely blunted in eNOS À/À mice.
Myocardial Perfusion Does Not Change With LNAME
Data from first-pass perfusion MRI acquired at baseline and after 4-mg/kg LNAME injection are shown in Figure 5 . Specifically, Figure 5a shows example AIF and TF curves from baseline and during NOS inhibition in one mouse. Both the AIFs and TFs are similar at baseline and 5 min after LNAME. Figure 5b summarizes the results from all LNAME perfusion data, showing that first-pass MRI in WT mice measured similar perfusion at baseline (6.2 6 0.4 mL/g/min) and 5 min after LNAME (6.1 6 0.6 mL/g/min), suggesting no vasodilatory effects (P ¼ not significant).
LNAME T 1 Mapping Detects eNOS Dysfunction in HFD Mice
Body weight was significantly higher in the HFD mice at 12 and 18 weeks after diet, and increased progressively with time (Fig. 6 ). Intravenous administration of 4-mg/kg LNAME caused a significant decrease in heart rate in mice fed a HFD for 12 and 18 weeks (Fig. 2) . The LNAME T 1 mapping results from mice fed a HFD compared with controls are shown in Figure 7 . Specifically, example R 1 maps from a HFD mouse after 18 weeks of diet show no observable change in R 1 when comparing the baseline (Fig. 7b) and post-LNAME R 1 maps (Fig. 7c) . A bar graph summarizing myocardial DT 1 results (T 1 measured 5 min after LNAME injection minus T 1 at baseline) is shown in Figure  7d for WT and HFD mice. These measurements detected a significant difference in DT 1 for mice fed a HFD for 12 and 18 weeks compared with mice fed a control chow diet (P < 0.01).
FIG. 7. Anatomical image (a)
, pre-LNAME R 1 map (b), and post-LNAME R 1 map (c) 18 weeks after initiation of HFD. One-way ANOVA detected significant differences in the change of myocardial T 1 assessed 5 min after LNAME injection between the HFD groups and the control mice fed a standard chow diet (d).
FIG. 6. Body weight was significantly higher in the HFD mice at 12 and 18 weeks after diet, and progressively increased with time (*P < 0.01).
DISCUSSION
The major finding of this study is that an increase in myocardial T 1 during NOS inhibition is a marker of coronary microvascular endothelial function, or, more specifically, of coronary microvascular eNOS function. Others have previously sought to image coronary endothelial function. For example, Hays et al showed that coronary artery cross-sectional area and blood flow before and during isometric handgrip exercise can be used to assess coronary endothelial function (26) . The present method uniquely probes the effect of inhibiting NOS on coronary microvascular permeability and, as demonstrated by the experiments in eNOS À/À mice, the effect was shown to be specifically mediated by eNOS. Thus, this method uses imaging to noninvasively probe the function of an enzyme that plays a key role in normal vascular physiology and in coronary microvascular pathophysiology.
In our experiments, we injected a bolus of LNAME and observed the system kinetics by imaging before and serially after the injection. The increase in myocardial T 1 observed at 5 min after LNAME injection is consistent with previous literature, in which light and electron microscopy detected opening of interendothelial junctions within a few minutes of injecting LNAME (9) . In the same study, it was also observed that the response to LNAME on interendothelial junctions opening lasted longer than 30 min, which is longer than the transient effect of LNAME on myocardial T 1 that we observed. This difference may be caused by the higher dose of LNAME that was used in the interendothelial junctions experiment (30 mg/kg versus 4 mg/kg), or the ex vivo context of the interendothelial junctions study as compared with our in vivo experiments. The return of T 1 toward baseline that we observed at 20 min after LNAME injection is likely caused by clearance by the lymphatic system, and the time course of our results is consistent with previous studies showing that acute edema causes gradual and significant elevation in the lymphatic flow rate within 30 min in the pulmonary (27, 28) and mesenteric lymphatic systems (29) .
Previous studies have shown that endothelial dysfunction is an early biomarker of vascular disease (30) (31) (32) (33) (34) (35) . In the present study, we detected coronary microvascular eNOS dysfunction at 12 and 18 weeks of HFD. Previously, we showed that myocardial perfusion reserve is impaired in HFD mice at 18 weeks of diet, but not at 12 weeks of diet (17) . Thus, our imaging methods show that coronary microvascular eNOS dysfunction precedes impairment of myocardial perfusion reserve, which is consistent with the current understanding of the progression of coronary vascular disease in HFD mice.
Others have applied myocardial T 1 mapping after the infusion of adenosine, and observed an increase in T 1 (14) . As adenosine is a vasodilator that increases blood flow and blood volume, that effect is attributed to vasodilation and an increase in myocardial blood volume. Our first-pass Gd-enhanced MRI experiments showed no change in myocardial blood flow. Moreover, LNAME is known to cause vasoconstriction. Given these results, it is unlikely that our observations of increased myocardial T 1 after injection of LNAME are caused by an increase in blood volume.
Our method probes microvascular eNOS function. In addition to the roles of eNOS in vasodilation, blood flow, and microvascular permeability, eNOS also plays important roles in inhibition of platelet aggregation and adhesion to the vascular wall (36) (37) (38) , an early event in the development of atherosclerosis, suppression of vascular smooth muscle cell proliferation (39) (40) (41) , and modulation of leukocyte-endothelial interactions (42) (43) (44) . Thus, methods to noninvasively assess eNOS function may be used in the future to shed light on the roles of microvascular eNOS in normal physiology and with regard to its various roles and functions.
Therapies that may prevent or treat eNOS dysfunction include bone marrow cell treatment (45, 46) , gene therapy (47, 48) , drugs targeting the renin-angiotensin-aldosterone system (12, 49, 50) , and statins (51) . The LNAME T 1 mapping may be a useful method to test whether therapeutic agents promote improved eNOS function.
The present study had several limitations. To keep the total anesthesia time under 2 h, we did not acquire whole-heart cine images, which would have provided heart weight and global left-ventricular function data. The LNAME causes an increase in blood pressure (5) . Even though NOS inhibition with intravenous LNAME has been used previously for human imaging studies (13) , the side effect of increased blood pressure is not conducive to routine use in human subjects. Nonetheless, this method may be useful for preclinical studies that investigate mechanisms underlying and therapies for coronary microvascular endothelial dysfunction. The method was well tolerated in serial MRI sessions in anesthetized mice. Although we showed that coronary microvascular endothelial dysfunction precedes impaired myocardial perfusion reserve in HFD mice, we did not determine the earliest time point at which coronary microvascular endothelial dysfunction can be detected in this disease model. Future studies may seek to more precisely determine the time of onset of coronary microvascular endothelial dysfunction in HFD mice. We used myocardial T 1 mapping but not T 2 mapping. The latter measurements would provide useful data, but the data acquisition times for current myocardial T 2 mapping sequences for mice (52, 53) are long compared with the timing of changes in myocardial relaxation times after LNAME injection, which precluded the acquisition of these data. By applying better acceleration methods, T 2 maps may be acquired in the future.
